|
Post by selluwud on Nov 16, 2021 15:39:14 GMT
Welcome to the ex-INMB shareholders club. I still love this company and am as optimistic as ever on their pipeline. I just think this could be a while until we hear any more meaningful updates from AD or INKmune and worry that this is dead money until then. I made great profits (for me) twice on this one and took a small loss this last time around. I’ll definitely keep it on my watchlist and re-evaluate things later next year. I'm still holding with gain/loss net at even. Though my current cost is way to high. I missed the opportunity to dump and will hold. Left holding the bag while the rest of the gang ran. Waiting until near end of year to weigh as a sell/loss to offset some tax gains, we'll see. All my green holdings are not biostocks!!!
|
|
|
Post by selluwud on May 24, 2022 11:38:02 GMT
Massive losses piling up here! Clinical hold is killing this one and the recent ATHX insignificant results have wiped me out. When I file taxes, my write offs will erase my tax burden for years to come. Biotech is not worth the risk it seems.
|
|
|
Post by JHam on May 24, 2022 13:04:47 GMT
Massive losses piling up here! Clinical hold is killing this one and the recent ATHX insignificant results have wiped me out. When I file taxes, my write offs will erase my tax burden for years to come. Biotech is not worth the risk it seems. Oh no, this is really too bad. I bet they will be able to resolve it pretty quickly, but this will delay things for sure. They may have to raise cash before the end of P2 now. Nothing is ever easy in biotech. I haven’t owned this own for a while now, but if it dips low enough today (below $4? $3?) then I may be a buyer. finance.yahoo.com/news/inmune-bio-inc-additional-manufacturing-200000526.html
|
|
|
Post by JHam on May 26, 2022 3:02:43 GMT
Massive losses piling up here! Clinical hold is killing this one and the recent ATHX insignificant results have wiped me out. When I file taxes, my write offs will erase my tax burden for years to come. Biotech is not worth the risk it seems. Oh no, this is really too bad. I bet they will be able to resolve it pretty quickly, but this will delay things for sure. They may have to raise cash before the end of P2 now. Nothing is ever easy in biotech. I haven’t owned this own for a while now, but if it dips low enough today (below $4? $3?) then I may be a buyer. finance.yahoo.com/news/inmune-bio-inc-additional-manufacturing-200000526.htmlDarn, I should have jumped in when I wrote this ($4.85). As suspected it has risen back over $6 now.
|
|